OncoMatch/Clinical Trials/NCT05488548
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Is NCT05488548 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies EP31670 for castrate resistant prostate cancer.
Treatment: EP31670 — A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Acute Myeloid Leukemia
Myeloproliferative Neoplasm
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: antiandrogen
Relapse or refractory castration-resistant prostate cancer (CRPC) following at least one anti-androgen regimen
Must have received: taxane (docetaxel)
Relapse or refractory castration-resistant prostate cancer (CRPC) following ... a docetaxel-containing regimen
Must have received: hypomethylating agent
relapsed or refractory CMML following at least 4 cycles of hypomethylating agent-containing regimen
Must have received: hydroxyurea (hydroxyurea)
relapsed or refractory CMML following ... hydroxyurea unless demonstration of progression or intolerance
Must have received: JAK inhibitor
advanced MF (intermediate or high-risk) following at least one JAK inhibitor-containing regimen
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL (Part 1); ANC ≥ 1,500/dL (Part 1); Platelet count ≥100,000/μL (Part 1) or ≥75,000/μL (Part 3)
Kidney function
Creatinine clearance (CLcr) ≥ 60 mL/min
Liver function
total bilirubin ≤ 1.5 x ULN; ALT or AST ≤ 2.5 x ULN or ≤ 5 x ULN in patients with liver metastases
Cardiac function
Internal normalized ratio for prothrombin time (INR) ≤ 1.2 in patients not receiving chronic anticoagulation; Corrected QT interval <470 msec
Adequate bone marrow function: Hemoglobin ≥ 9.0 g/dL (Part 1); ANC ≥ 1,500/dL (Part 1); Platelet count ≥100,000/μL (Part 1) or ≥75,000/μL (Part 3). Adequate renal function: Creatinine clearance (CLcr) ≥ 60 mL/min. Adequate liver function: total bilirubin ≤ 1.5 x ULN; ALT or AST ≤ 2.5 x ULN or ≤ 5 x ULN in patients with liver metastases. Internal normalized ratio for prothrombin time (INR) ≤ 1.2 in patients not receiving chronic anticoagulation. Corrected QT interval <470 msec.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Arizona · Phoenix, Arizona
- Mayo Clinic Florida · Jacksonville, Florida
- Dana Farber Cancer Institute · Boston, Massachusetts
- Mayo Clinic Rochester · Rochester, Minnesota
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify